A phase I/II clinical trial combining CIMAvax-EGF with nivolumab, as second line in NSCLC is open and recruiting patients at the Roswell Park Comprehensive Cancer Center (NCT02955290). This evidence concerns the gene EGF and non-small cell lung carcinoma.